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The Mechanism of Melanoma-Associated Thrombin
Activity and von Willebrand Factor Release from
Endothelial Cells
Nina Kerk1, Elwira A. Strozyk2,3, Birgit Po¨ppelmann1 and Stefan W. Schneider2
Activation of the coagulation system in malignancy enables tumor spreading and is thus associated with poor
prognosis for the patient. In this study, we analyzed the in vitro mechanisms by which two human metastatic
melanoma cell lines, MV3 and WM9, transform the vascular endothelium into a prothrombotic activated state.
We show that both melanoma cell lines activate prothrombin due to tissue factor (TF) expression by showing
that thrombin generation was blocked with a TF-neutralizing antibody and TF-siRNA. In addition, using the
cysteine protease inhibitor E-64, we excluded the formerly described cancer procoagulant (CP) as a major factor
contributing to thrombin generation. Furthermore, we describe a direct thrombin-independent response of
endothelial cells (ECs) to MV3-derived supernatant as measured by rapid release of VWF. We also show that two
clinically approved LMWHs, tinzaparin and enoxaparin, are effective inhibitors of thrombin generation and
thrombin activity in plasma. Furthermore, our data indicate a protective effect of heparins on EC activation as
shown by reduced VWF release in response to MV3 supernatant. These promising effects of heparins on the
melanoma-induced thrombotic conditions justify further clinical investigations in the field of oncology.
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INTRODUCTION
The link between cancer and hypercoagulopathy was first
suggested by Trousseau nearly 150 years ago (Trousseau,
1865). A plethora of cancer cells were shown to elicit
procoagulant activities by interaction with the plasmatic
coagulation system as well as with platelets, leukocytes, and
endothelial cells (ECs) (Rickles et al., 2003; Falanga et al.,
2009). Importantly, tumor-associated activation of blood
coagulation not only bears the risk of thromboembolism but
also facilitates tumor metastasis, which is the most delete-
rious event leading to the mortality of cancer patients (Kakkar,
2009). The main procoagulant activity of cancer cells has
been ascribed to the expression of tissue factor (TF), a
transmembrane receptor also referred to as thromboplastin.
Present on the surface of fibroblasts, epithelial cells, at the
boundaries of organs, and synthesized de novo in ECs and
circulating monocytes (Mackman, 2004), TF is the primary
initiator of blood coagulation. It is normally separated from
the blood stream unless it is exposed to circulating coagula-
tion factor VII, that is, upon vascular damage. In this case TF
activates factor X (FX) leading, through the FX/FV (prothrom-
binase) complex, to the generation of thrombin and
subsequent platelet activation (Mackman, 2004). Interest-
ingly, TF-mediated thrombin generation has been shown to
enhance hematogenous metastasis in experimental animal
models (Mueller et al., 1992). Accordingly, overexpression of
anticoagulatory thrombomodulin (TM), a surface receptor
inactivating thrombin, was shown to have an inhibitory effect
on tumor growth (Zhang et al., 1998) and was postulated to
be a positive predictive and prognostic factor (Zhang et al.,
1998; Hanly et al., 2005, 2006).
Thrombin action supporting tumor spreading and metas-
tasis is predominantly mediated through the cleavage and
activation of proteinase-activated receptor-1 (PAR-1), which
is expressed by platelets, ECs, and preferentially highly
metastatic cancer cell lines (Nierodzik et al., 1998; Belting
et al., 2005). The important role of the thrombin/PAR-1
pathway in malignancy was shown by using experimental
melanoma mouse models where a dramatic fold induction of
lung metastases was observed with thrombin-treated as
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compared with that in untreated cancer cells (Nierodzik
et al., 1992, 1998; Arora et al., 2007; Melnikova et al.,
2008). Interestingly, our group and others have recently
postulated that the matrix metalloproteinase-1 (MMP-1)
secreted, for example, by metastatic cancer cells or tumor-
activated fibroblasts, is an additional activator of PAR-1
(Boire et al., 2005; Loffek et al., 2005; Goerge et al., 2006).
We could show that melanoma supernatants activate ECs
through the MMP-1/PAR-1 axis, followed by secretion of the
proinflammatory and prothrombotic content of the Weibel–-
Palade bodies (WPB), intracellular storage granules for IL-8,
P-selectin, and von Willebrand factor (VWF) (Goerge et al.,
2006; Huck et al., 2007).
Synthesized by megakaryocytes and ECs, VWF is present
in platelets, ECs, sub-endothelium, and plasma as a large
multimeric glycoprotein that mediates the initial adhesion of
platelets in thrombus formation, which is essential in primary
hemostasis (Ruggeri, 2003). Interestingly, expression of
adhesive ligands for VWF has been reported in cancer cells
as well (Nierodzik et al., 1995, 1998) and experimental
studies have shown a direct interaction between VWF and
neoplastic cells (Terraube et al., 2006). In fact, previous
studies of our group have shown that melanoma cell-derived
soluble factors induce massive release and immobilization of
ultra-large VWF (ULVWF) fibers at the luminal EC membrane,
which efficiently bound platelets (Goerge et al., 2007;
Schneider et al., 2007). This binding presumably contributes
to a microvascular arrest and activation of platelets, which is
known to be involved in the establishment of metastasis
(Borsig, 2008). Thus, VWF is emerging as having a pivotal
role in the metastatic process. Indeed, elevated plasma levels
of VWF have been shown to correlate with enhanced tumor
progression in patients (Damin et al., 2002). In line with these
results, it was shown that blocking antibodies to VWF
attenuate melanoma cell progression in a mouse model
(Karpatkin et al., 1988). By contrast, in a recent publication it
has been reported that lung colonization by cancer cells is
enhanced in VWF-knockout mice (Terraube et al., 2006). The
mechanism of VWF-mediated tumor spreading remains
elusive, but may be related to the different cell types
releasing VWF (platelets or ECs) and to the structure–function
relationship of VWF as published previously (Schneider et al.,
2007).
In vitro and in vivo studies using mouse models have also
shown that spontaneous and induced metastasis is efficiently
inhibited by anticoagulants (Falanga and Piccioli, 2005;
Niers et al., 2007; Stevenson et al., 2007). In this context,
unfractionated heparin (UFH) and low-molecular-weight
heparins (LMWHs) widely used for prophylaxis and treatment
of thrombosis are now expected to be beneficial for patients
with malignancy. This increasing interest in heparins is
supported by clinical studies suggesting a survival benefit of
patients treated with LMWHs (Lazo-Langner et al., 2007).
UFH and LMWHs basically exert their anticoagulant effects
by activating the physiological coagulation inhibitor antith-
rombin III, which neutralizes the serine proteases involved in
the coagulation cascade, particularly activated factor X and
thrombin (FIIa) (Hemker and Be´guin, 1990).
Interestingly, UFH and LMWHs have additionally been
shown to affect several steps in cancer progression through
non-anticoagulant actions like heparanase inhibition, binding
of cytokines and growth factors (Castelli et al., 2004), and, in
particular, inhibition of P-selectin-mediated cancer cell
adhesion (Ludwig et al., 2004; Borsig, 2007; Simonis et al.,
2007) and induction of TF pathway inhibitor release
(Amirkhosravi et al., 2003). These findings indicate a variety
of heparin functions in cancer biology that have not yet been
fully uncovered.
The aim of this study was to assess the procoagulant
activities of two phenotypically distinct metastatic melanoma
cell lines, WM9 and MV3, and to characterize the role of the
melanoma-expressed factors in thrombin generation. Further-
more, we analyzed the effect of LMWHs on melanoma-
mediated thrombin generation and the melanoma–EC
interaction to explore the effect of heparins in the context
of tumor spreading and metastasis formation.
RESULTS
Melanoma cells express TF and TM
The cancer cell-mediated activation of blood coagulation
facilitating malignant tumor growth and metastasis has been
attributed to TF-dependent and TF-independent mechanisms
(Rickles et al., 2003; Falanga et al., 2009). To assess the
underlying mechanism linking malignant cells and blood
coagulation, the expression of TF and its physiological
antagonist TM was examined in two metastatic melanoma
cell lines, MV3 and WM9, by fluorescence-activated cells
sorting (FACS) analysis (Figure 1). Procoagulatory TF was
detectable on the surface of both melanoma cell lines
(Figure 1), however WM9 cells showed an about 1.7-fold
higher expression than MV3 cells (mean fluorescence
intensity shift±SD was 3.66±0.88 and 2.13±0.5, respec-
tively). On the contrary, TM expression was predominant on
the MV3 and almost undetectable on the WM9 cells (mean
fluorescence intensity shift±SD was 3.48±1.22 and
1.41±0.28, respectively). Accordingly, staining of permea-
bilized cells (Supplementary Figure S1 online) showed a
similar expression pattern and only marginal intracellular
accumulation of TF or TM molecules (mean fluorescence
intensity shift±SD; TF: 5.11±1.07 and 4.13±0.44;
TM: 1.44±0.37 and 3.20±1.36 for WM9 and MV3,
respectively).
Thus, FACS measurements indicate that melanoma cells
express both TF and TM but to different extents.
TF is the major player in melanoma cell-induced thrombin
generation
To investigate the procoagulant activity of WM9 and MV3 in
blood plasma, thrombin generation was measured in an
in vitro assay using the chromogenic substrate S-2238, which
requires active thrombin for its cleavage. As shown in
Figure 2 both cell lines were able to generate thrombin
activity in plasma, whereas WM9 showed a higher capacity
than MV3. Addition of the cysteine protease inhibitor E-64
(100 mM), known to abolish the activity of the previously
described cancer procoagulant (CP) (Gordon and Cross,
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1981; Rickles et al., 2003), did not alter melanoma-induced
thrombin activity (Figure 2a). By contrast, incubation of WM9
and MV3 cell lysates with an anti-human TF antibody
(10 mgml1) led to a decrease of thrombin activity, which
was comparable to the thrombin activity measured in a
control plasma (¼plasma baseline) (Figure 2a). The plasma
baseline level represents the coagulatory potential
of plasma without cancer-associated factors and was used
as a control.
Furthermore, WM9 and MV3 cells were transfected with a
TF- or TM-specific small interfering RNA (siRNA) before the
chromogenic assay was performed. TM was knocked down to
evaluate whether the absence of this natural anticoagulant
might potentiate thrombin generation. Hirudin, the natural
inhibitor of thrombin, was used as a positive control. Upon
downregulation of TF (Supplementary Figure S2a and S2b
online) both melanoma cell lines showed reduced thrombin
generation, which was comparable to the thrombin genera-
tion measured in a control plasma (¼ plasma baseline)
(Figure 2b). Interestingly, upon downregulation of TM
thrombin activity was slightly enhanced in the case of MV3
cells, but no significant difference was detected between the
transfected and non-treated WM9 cells (Figure 2b).
Thus, TF but not CP blockade diminished the thrombin
activity measured in the presence of WM9 and MV3 cell
lysates. Furthermore, as TM seems to have a minor role, these
data show that melanoma-mediated thrombin generation
depends mainly on a functional TF.
LMWHs inhibit melanoma cell-triggered thrombin generation
In our study, we were interested to know whether LMWHs
have an effect on the melanoma cell-mediated generation of
thrombin, an important promoter of invasion and metastasis
(Nierodzik et al., 1992; Hu et al., 2004). To characterize the
actions of LMWHs in this context, MV3 or WM9 cell lysates
were supplemented with tinzaparin or enoxaparin at a final
concentration of 1Uml1 (Figure 3). Two different time
points were chosen for analysis. First, LMWHs were added
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Figure 1. Expression of TF and TM on the surface of MV3 and WM9
melanoma cells. For membrane-bound protein detection cells were harvested
by accutase and subjected to staining with antibodies specific to TF or to TM.
Subsequently, cells were analyzed by flow cytometry. The histograms show
the fluorescence intensity (x-axis) projected against the cell number
(y-axis) of the stained cells (open black line) in comparison with an isotype
control (filled grey histograms). The data show one representative out of three
independently performed experiments.
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Figure 2. Melanoma-mediated thrombin generation mainly depends on TF.
Thrombin generation was measured as described under Materials and
Methods. (a) MV3 and WM9 cell lysates (5 105 cellsml1) were treated with
E-64, a cysteine protease inhibitor (100mM), or a polyclonal antibody against
human TF (10 mgml1) (n¼ 3 per group). (b) MV3 and WM9 cells were non-
treated or transfected with TF-siRNA, TM-siRNA, or a non-silencing siRNA
(Neg.). The cell lysates of the transfected and non-treated melanoma cells
were subjected to a thrombin generation assay. Hirudin (1Uml1) served as a
positive control (n¼6 per group). All data are shown as the mean maximal
rate of cleavage (vmax)±SD. Ab, antibody. *Po0.05, ***Po0.005.
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before starting the coagulation reaction to analyze the
inhibition of the upstream factors, like FX, engaged in
prothrombin activation. Second, heparins were added after
thrombin generation immediately before measurement of
substrate cleavage, to test whether tinzaparin or enoxaparin,
which vary in their anti-X/anti-II (thrombin) activity ratio
(tinzaparin: 1.6oenoxaparin: 3.9), could neutralize and/or
inactivate thrombin in the plasma directly. Hirudin served as
a positive control and was added immediately before
measurement of substrate cleavage. Surprisingly, tinzaparin
and enoxaparin were both capable of blocking the chromo-
genic substrate cleavage to the control level of the plasma
baseline. This effect was independent of the time of LMWH
addition suggesting inhibition of both thrombin generation
and activity.
VWF release and formation of ULVWF in response to thrombin
and melanoma cell supernatant
As shown in Figures 2 and 3 malignant melanoma cells are
able to trigger the generation of thrombin, a known activator
of PAR-1-dependent acute EC response. In addition, mela-
noma cell-derived MMP-1 can directly activate ECs through
PAR-1. This cancer-induced EC activation is followed by
acute release of vasoactive VWF, a marker of EC procoagu-
latory response (Goerge et al., 2006, 2007). Here, we
compared the effect of thrombin- versus non-thrombin-
induced VWF release mediated by MV3 or WM9 super-
natant. By knockdown of MMP-1 in MV3 cells we could
prove that MV3 supernatant-derived MMP-1 activates EC
followed by VWF release. However, WM9 cells (non-
transfected or after downregulation of MMP-1) did not induce
any VWF release (Figure 4a). Furthermore, human umbilical
vein ECs (HUVECs) or human dermal microvascular ECs
(HDMECs) were stimulated with the MV3 or WM9 cell
supernatant with or without addition of exogenous thrombin
(0.5Uml1) and EC supernatants were harvested for quanti-
tative analysis of VWF release by ELISA (Figures 4b and c).
Cells were stained for fluorescence microscopy to image and
prove the release of ULVWF as a result of WPB exocytosis
(Figure 5). The results show that the MV3 supernatant alone
induced a significant increase of VWF release in both
HUVECs (Figure 4b) and HDMECs (Figure 4c), which was
not further enhanced by thrombin addition. The WM9
supernatant was able to induce such EC activation only in
the presence of thrombin. VWF release increased three-fold
in the HUVECs (Figure 4b) and two-fold in the HDMECs
(Figure 4c), and this effect was inhibited by hirudin indicating
thrombin dependency. The quantitative results of VWF
release were confirmed by immunofluorescence experiments
on ULVWF formation. Non-treated HUVECs (Figure 5a) and
HDMECs (Figure 5e) show VWF stored in the WPBs. In
comparison, 15minutes of stimulation with the MV3 super-
natant led to WPB exocytosis followed by release of ULVWF
immobilized on the surface of the HUVECs (Figure 5b) or the
HDMECs (Figure 5f). After addition of thrombin to the MV3
supernatant, no pronounced ULVWF release was detected
(Figures 5c and g). Furthermore, VWF fibers were still
detected after stimulation with MV3 supernatant supplemen-
ted with thrombin and hirudin (data not shown). These data
are in line with the quantitative results from the VWF ELISA
measurements (Figures 4b and c) and indicate a thrombin-
independent pathway. By contrast, the image produced upon
EC stimulation with the WM9 supernatant did not differ from
the control image, showing no ULVWF fibers (data not
shown). However, ULVWF fibers were visible after stimula-
tion with the thrombin-supplied WM9 supernatant (Figures
5d and h), which could be reversed by hirudin (data not
shown).
These data demonstrate that in addition to thrombin-
dependent EC activation an alternative pathway, most
probably through the MMP-1/PAR-1 axis (Figure 4a), shows
a comparable efficacy in EC activation.
Heparins attenuate MV3-induced EC activation
As MV3 supernatants are able to directly activate ECs we also
analyzed the effect of UFH, tinzaparin, and enoxaparin
(50Uml1) on VWF release (Figure 6). Interestingly, MV3-
induced direct activation of ECs was moderately diminished
upon incubation with heparins as shown for the HDMECs
(Figure 6) and the HUVECs (Supplementary Figure S3 online).
In particular, tinzaparin attenuated VWF release from both EC
types (HDMECs and HUVECs).
By contrast, in the absence of plasmatic factors the WM9
supernatant with or without addition of heparins had no
effect on VWF release (Supplementary Figure S3 online).
DISCUSSION
Considerable progress in cancer therapy has been documen-
ted over the last decade; however, no real improvement in
the management of metastatic malignant melanoma has been
achieved (Lorigan et al., 2008). Therefore, it is necessary to
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Figure 3. Inhibition of melanoma cell-triggered thrombin generation by
LMWHs. Tinzaparin (1Uml1) or enoxaparin (1Uml1) was added to MV3
and WM9 cell lysates at two different time points: first, at the beginning of the
assay (‘‘early’’) and second, after stopping thrombin generation (‘‘late’’).
Hirudin (1Uml1) was added at the second time point as a positive control.
The results showing thrombin activity are expressed as the mean maximal rate
of substrate cleavage (vmax)±SD of five independent experiments. Enoxa,
enoxaparin; Tinza, tinzaparin. ***Po0.005.
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consider the different aspects of cancer progression as
potential targets for therapeutic approaches. A growing body
of evidence indicates that therapies directed at the mechan-
isms that contribute to the hypercoagulability associated with
cancer bear a beneficial impact for the patients’ outcome
(Rickles et al., 2001; Kakkar, 2009). Several data and
reports from animal models suggest that both the immune
modulation by melanoma-derived factors (Ilkovitch and
Lopez, 2008) and the local coagulation activation induced
by cancer cells support tumor spreading (Rickles et al., 2001).
Assessing the procoagulant properties of two different
melanoma cell lines (MV3 and WM9), we could show that
TF is the major player in the melanoma-mediated activation
of thrombin. In this context, we excluded the involvement of
CP, a formerly discussed cysteine protease, which is
associated with a malignant phenotype (Gordon and Cross,
1981; Donati et al., 1986; Gordon and Mielicki, 1997).
Application of the CP inhibitor E-64 (Falanga and Gordon,
1985) did not significantly affect melanoma-associated
thrombin generation, whereas neutralization or knockdown
of TF inhibited it almost completely. Therefore, we conclude
that TF and not CP is the major player in melanoma-mediated
thrombin generation. Recently, the procoagulant activity of
MV3 melanoma cells was investigated by Geaquinto et al.
(2008) who postulated an alternative TF-independent me-
chanism of thrombin generation through recruitment of
activated factor X from serum. We cannot confirm this
hypothesis, possibly due to the fact that we used normal
human plasma in which all clotting factors were present. In
our study, the lack of procoagulant activity of melanoma cells
after blockade or knockdown of TF, despite the presence of
clotting factors, provides evidence for an exclusive TF-
dependent pathway of thrombin generation. Our suggestion
that TF is the main source of melanoma cell-promoted
thrombin generation, a prerequisite for tumor spreading, is in
line with previous studies indicating that TF overexpression
alters the cancer cell phenotypic behavior and results in both
enhanced cancer cell invasion in vitro and enhanced
metastatic potential in vivo (Mueller et al., 1992; Fischer
et al., 1995; Amirkhosravi et al., 2002).
Melanoma-promoted thrombin generation could however
also result from a lack of TM expression. Indeed, TM was
shown to block the procoagulant activities of TF (Esmon
et al., 1982, 1983) and inhibit the invasive activity of mouse
melanoma cells in vitro (Hosaka et al., 2000). Therefore, TM
provides a potential therapeutic anticancer target (Hanly
et al., 2005, 2006). Interestingly, expression of procoagula-
tory TF and anticoagulatory TM in melanoma cells was
inversely related as TM was highly expressed in low TF-
expressing MV3 cells and vice versa in WM9 cells. However,
TM knockdown in MV3 cells resulted in only a moderate
increase in thrombin activity and had no effect in WM9 cells.
In summary, we show that TF remains the predominant
thrombin mediator during cancer-associated coagulation.
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Figure 4. Effect of MMP-1 or thrombin on acute melanoma cell-induced EC
activation. EC supernatants were analyzed for VWF release by ELISA. (a)
Melanoma cells were transfected with MMP-1-siRNA or a non-silencing-
siRNA (Allstars). HUVECs were stimulated for 15minutes with supernatants
harvested from transfected or non-treated cells. HBRS served as a negative
control. HUVECs (b) and HDMECs (c) were stimulated for 15minutes with the
MV3 or WM9 supernatant alone (non-treated), or supernatant supplemented
with thrombin (0.5Uml1) with or without addition of hirudin. HBRS served
as a negative control and hirudin (1Uml1) was used to inhibit any effect of
thrombin. All results are expressed as VWF release in ngml1 and presented
as the mean±SD of at least three independent experiments. Sn, supernatant;
Thr, thrombin. ***Po0.005.
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It is conceivable that the TF–thrombin pathway represents
a promising target for anticancer therapies. Indeed, several
antagonists such as the TF pathway inhibitor, hirudin, or
LMWHs have been evaluated in diverse animal models
(Amirkhosravi et al., 2002; Hu et al., 2004; Im et al., 2004).
In particular, LMWHs have been shown to exhibit minor
adverse drug reactions and prevent cancer spreading
(Amirkhosravi et al., 2003; Lee et al., 2003; Stevenson
et al., 2005; Ludwig et al., 2006). Among a plethora of
potential antimetastatic effects of LMWHs, inhibition of
P-selectin and release of EC-derived TF pathway inhibitor
were suggested to be the most effective mechanisms (Ludwig
et al., 2004, 2006; Borsig, 2007).
In addition, some clinical trials, originally not targeted at
assessing the anticancer properties of heparins, indicate a
prolongation of survival in cancer patients receiving LMWHs
for thrombosis prophylaxis (Kakkar et al., 2004; Klerk et al.,
2005; Lee et al., 2005). The therapeutic success was
comparable to modern antitumor drugs whereas LMWHs
are less expensive, show marginal side effects, and do not
need laboratory monitoring due to a favorable safety profile.
In our study, we analyzed the effect of two different LMWHs,
tinzaparin and enoxaparin, on melanoma cell-induced
thrombin generation and EC activation. We could show that
both LMWHs inhibit the melanoma-mediated generation of
thrombin, which indicates their potential to prevent throm-
bin-supported melanoma progression.
Various studies indicate that the actions of thrombin
associated with tumor spreading, like activation of platelets
and ECs, as well as clot formation and clotting-independent
effects, are mediated by the PAR (Fischer et al., 1995;
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Figure 5. Secretion of luminal ULVWF after EC activation. Immunofluorescence staining of ULVWF secreted by HUVECs (a–d) or HDMECs (e–f) was performed
after a 15minute-treatment with either HBRS as a negative control (a/e), MV3 supernatant (b/f), MV3 supernatant supplemented with thrombin (0.5Uml1)
(c/g), or WM9 supernatant supplemented with thrombin (0.5Uml1) (d/h). The images are representative of three independent experiments. The insets show
a magnified view of the ULVWF fibers secreted luminally by the HDMECs. Bar¼ 20 mm. Sn, supernatant; Thr, thrombin.
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Figure 6. Effect of UFH, tinzaparin, or enoxaparin on acute melanoma cell-
induced EC activation. HDMECs were stimulated for 15minutes with the
MV3 supernatant either with or without addition of UFH, tinzaparin, or
enoxaparin (50Uml1). The results are expressed as % of MV3 supernatant-
induced VWF release and presented as the mean±SD of at least three
independent experiments. Enoxa, enoxaparin; Sn, supernatant; Tinza,
tinzaparin. *Po0.05, ***Po0.005.
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Nierodzik et al., 1998; Tellez and Bar-Eli, 2003). Interest-
ingly, cancer cell-secreted MMP-1 was recently shown to
activate EC-expressed PAR-1 as well, followed by WPB
exocytosis and ULVWF release (Goerge et al., 2006). In this
study we show that the MV3 supernatant but not the WM9
supernatant was able to induce an acute activation of
HUVECs and HDMECs despite the absence of all coagulation
cofactors. A thrombin-independent pathway must have been
involved as the extent of VWF release could be neither
inhibited by hirudin nor further enhanced by addition of
thrombin. Therefore, we concluded that the recently shown
PAR-1 activator MMP-1 was involved in the MV3 cell-
mediated EC activation. This hypothesis could be confirmed
by a diminished response of HUVECs to treatment with
supernatant obtained from MMP-1-siRNA-transfected
MV3 cells. By contrast, the WM9 supernatant was able to
promote acute EC activation and VWF release only in the
presence of thrombin. Interestingly, WM9 cells were more
potent than MV3 cells in generating thrombin in plasma,
probably due to their higher expression of TF. In light of these
results it is tempting to speculate that melanoma cells of the
WM9 phenotype, in contrast to those of the MV3 phenotype,
mainly affect the ECs through the TF/thrombin/PAR-1 axis.
Taken together, our findings indicate that melanoma cell
phenotypes vary in their procoagulant activities as they not
only differed in their ability to induce thrombin generation,
but also in their potency to activate ECs directly. Of high
interest was the evaluation of potential heparin actions in the
context of the melanoma cell–EC communication. Astonish-
ingly, heparins were able to attenuate the acute MV3
supernatant-mediated VWF release from the ECs. Thus, our
results suggest an additional protective role of heparins, in
particular tinzaparin, in the melanoma cell–EC communica-
tion, next to their ability to inhibit TF-mediated thrombin
generation.
In fact, our results are in agreement with several studies
reporting that heparins exert an anti-platelet, anti-inflamma-
tory, and endothelium-protective action in vivo supplemen-
tary to their benefit in the cancer patients’ outcomes
mentioned above (Cadroy et al., 1996; Castelli et al., 2004;
Lazo-Langner et al., 2007).
In summary, we could show that melanoma cells exert
diverse procoagulatory effects on ECs. One pathway is
dependent on TF-mediated thrombin generation followed
by EC activation through PAR-1 cleavage. A second
alternative pathway can act through melanoma-derived
MMP-1, which directly stimulates ECs comparable to
thrombin and possibly through cleavage of PAR-1 receptors
(Goerge et al., 2006). The latter pathway is postulated for
MV3-induced EC activation. Both pathways ultimately lead
to acute WPB exocytosis and luminal release of ULVWF.
ULVWF fibers were shown to be immobilized on the luminal
EC surface where they act as binding partners for platelets
and circulating cells (Denis, 2002; Goerge et al., 2006).
It is well accepted that the procoagulatory activities of
malignant cells enhance the risk of metastasis. Indeed, an
understanding of the molecular mechanism of the cancer
cell–EC interaction, leading to a proinflammatory and
procoagulatory milieu, provides new targets and directions
for future advances concerning the treatment of tumor-
associated thrombosis and tumor spreading. In this context
heparins are excellent candidates, which deserve further
investigation.
MATERIALS AND METHODS
Cell culture
The human metastatic melanoma cell lines WM9 and MV3 were
maintained at 37 1C, 5% CO2 in DMEM (PAA, Pasching, Austria)
containing enriched Earle’s salts, non-essential amino acids,
glutamic acid, and 10% heat-inactivated fetal calf serum
(Boehringer Mannheim, Mannheim, Germany). HUVECs were
isolated using collagenase and grown in M199 culture medium
(Life Technologies, Karlsruhe, Germany) supplemented with 10%
heat-inactivated fetal calf serum, antibiotics (penicillin and strepto-
mycin), 5Uml1 heparin (Biochrom, Berlin, Germany), and 1%
growth supplement derived from bovine retina as described
previously (Goerge et al., 2002). HUVECs were maintained at
37 1C, 5% CO2 and cultivated maximally up to the third passage.
HDMECs were purchased from PromoCell (Heidelberg, Germany)
and maintained in Endothelial Cell Growth Medium MV (PromoCell,
Heidelberg, Germany). HDMECs were maintained at 37 1C, 5% CO2
and cultivated maximally up to the sixth passage. For some
experiments, cells were incubated in HEPES-buffered Ringer solution
(HBRS) consisting of 140mmol l1 NaCl, 5mmol l1 KCl, 1mmol l1
MgCl2, 1mmol l
1 CaCl2, 5mmol l
1 glucose, and 10mmol l1
HEPES.
Generation of melanoma-derived supernatants
For standardized generation of supernatants, melanoma cells were
grown to confluence, the culture medium was removed, and the
cells were intensely rinsed twice with HBRS. After incubation in 5ml
HBRS for 8 hours, the conditioned melanoma-derived supernatant
was harvested from the intact cell layer and centrifuged to remove
cell debris. Finally, the supernatants were frozen at 20 1C until
experiments were performed.
Fluorescence-activated cell sorting
Melanoma TF and TM expression was analyzed by an indirect
immunofluorescence staining procedure. Cells were harvested with
accutase (PAA, Pasching, Austria), washed with phosphate-buffered
saline (PBS), and divided for membrane-bound and intracellular
protein detection. For surface staining cells were incubated on ice
with 1 mg of a primary mouse anti-human TF or mouse anti-human
TM antibody (American Diagnostica, Stamford, CT) or an isotype
control in HRBS (containing 1% fetal calf serum) for 30minutes. The
cells were washed and incubated with an FITC-conjugated
secondary antibody (Invitrogen, Paisley, UK) at equal incubation
conditions. For intracellular protein detection, cells were fixed with
4% formaldehyde in PBS, permeabilized with 0.3% saponine
(Sigma-Aldrich, Deisenhofen, Germany) in PBS, and incubated with
the first antibody or an isotype control overnight at 4 1C. The
secondary FITC-labeled antibody (Invitrogen, Paisley, UK) was
incubated in PBS (containing 0.3% saponine) on ice for 30minutes.
After the staining procedure 10,000 cells were analyzed with the
FACS Canto and Diva Software (Becton Dickinson, Heidelberg,
Germany).
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Stimulation of HUVECs and HDMECs with melanoma
supernatant and thrombin
HUVECs or HDMECs were grown on gelatin-coated glass coverslips.
After they had reached confluence, the cells were washed twice with
pre-warmed HBRS, mounted on a microfluidic device modified for
EC culture (Huck et al., 2007; Schneider et al., 2007), and
subsequently perfused either with a stimulus in HBRS or with
melanoma supernatants for 15minutes. Various stimuli were added
as indicated in the Results section: human thrombin (0.5Uml1)
(Sigma-Aldrich, Deisenhofen, Germany), UFH (1Uml1 or
50Uml1) (Liquemin; Roche, Mannheim, Germany), tinzaparin
(1Uml1 or 50Uml1) (Innohep; Leo Pharma, Ballerup, Denmark),
enoxaparin (1Uml1 or 50Uml1) (Clexane; Aventis Pharma,
Frankfurt/Main, Germany), or hirudin (1Uml1) (Pentapharm,
Munich, Germany). The liquid flow in the microfluidic device was
driven by a surface acoustic wave electrically excited on a
piezoelectric substrate (LiNbO3) using interdigital transducers. The
surface acoustic wave interacting with the confined liquid at the
solid/liquid interface drove the liquid to acoustic streaming. During
the experiments the chamber was placed on a thermal plate to
maintain a constant temperature of 37 1C. Flow rates of
20 dyne cm2 were used to ensure VWF activation. After the
perfusion period, the HUVEC or HDMEC supernatants were
harvested and kept at 20 1C until measurement by VWF ELISA.
The cells on coverslips were subjected to immunofluorescence
staining.
Immunofluorescence staining of endothelium-derived ULVWF
HUVECs were immediately fixed using ice-cold methanol.
After washing and blocking with 2% BSA in an incubation buffer
(0.3% Triton X-100; 0.1% BSA in HBRS), the samples were labeled
using a rabbit anti-VWF antibody (Dako, Copenhagen, Denmark)
(1:200) and a mouse anti-tubulin antibody (Sigma-Aldrich,
Taufkirchen, Germany) (1:400). The cells were intensively washed
and secondary labeling was performed by incubation with anti-
rabbit Qdot 605 and anti-mouse Qdot 525 (Invitrogen,
Hayward, CA) in incubation buffer. Coverslips were mounted in
mowiol–glycol solution with freshly added 50mgml1 DABCO (1.4-
diazabicyclo-[2.2.2]octane; Sigma-Aldrich, Taufkirchen, Germany).
Fluorescence imaging was performed using a Zeiss Axiovert 200
microscope connected to a CCD camera system (CoolSnap HQ;
Photometrics, Tucson, AZ) and processed using the SPOT Advanced
imaging software version 3.1.0 (Diagnostic Instruments, Sterling
Heights, MI).
For surface staining, HDMECs were immediately fixed using 4%
ice-cold formaldehyde in 100mM sodium phosphate buffer/4%
sucrose at 4 1C for 1 hour. After washing and blocking with 2% BSA
in 100mM sodium phosphate buffer/4% sucrose, the samples were
labeled using a rabbit anti-VWF antibody (Dako, Copenhagen,
Denmark) (1:200). Secondary labeling was performed by incubation
with goat anti-rabbit-FITC (BD Pharmingen, San Diego, CA) (1:400)
in sodium phosphate buffer/4% sucrose/0.5% BSA at room
temperature for 1 hour. Finally, coverslips were mounted in
DABCO–mowiol–glycol solution. Fluorescence imaging was per-
formed using a Zeiss Observer.Z1 microscope (Carl Zeiss AG,
Oberkochen, Germany) connected to a CCD camera system (Carl
Zeiss AxioCam MRm 3) and processed using the AxioVision software
version 4.8.0.0.
Quantitative VWF measurements using ELISA
Release of VWF was measured by a sandwich ELISA technique
using a polyclonal rabbit anti-VWF antibody (Dako, Copenhagen,
Denmark) and a polyclonal rabbit peroxidase-labeled anti-human
VWF antibody (Dako, Copenhagen, Denmark). A standard curve
was generated using Standard Human Plasma (Behring, Marburg,
Germany) with a defined VWF content (2nd International Standard
87/718, National Institute for Biological Standards and Control,
London).
Determination of thrombin generation and activity using
chromogenic assay
With little modification thrombin activity was assayed as described
previously (Martinez-Sales et al., 2003). Briefly, 5 105 WM9 or
MV3 cells were seeded on 6-mm dishes, cultured for 24 hours, and
washed twice with PBS. The cells were disrupted by three
freeze–thaw cycles in PBS. Platelet-poor normal plasma pooled
from healthy volunteers was prepared by a two-step centrifugation
process: 3,000 g at 4 1C for 15minutes followed by 11,000 g for
5minutes. Plasma aliquots were stored at 20 1C until use and
thawed at 37 1C. One well of a 96-well plate was filled with
50 ml of MV3 or WM9 cell lysates and 50 ml of 1:15 PBS-diluted
platelet-poor normal plasma. After incubation for 2minutes at
37 1C the coagulation reaction was started by adding 5ml of
250mM CaCl2. The reaction was performed at 37 1C and stopped
after 15minutes by adding EDTA. Finally, hydrolysis of a specific
thrombin chromogenic substrate S-2238 (Chromogenix-Instrumenta-
tion Laboratory Spa, Milano, Italy) at a final concentration of 0.2mM
was used to show the generation and enzymatic activity of thrombin.
Absorbance was measured continuously (once per minute) at
405 nm, 37 1C, for 60minutes using an microplate reader and
analyzed using the Gen 5 Data Analysis Software (BioTek Instru-
ments, Bad Friedrichshall, Germany). The results are expressed as
maximal rate of cleavage (vmax). For some experiments, the protease
inhibitor E-64 (Calbiochem, Darmstadt, Germany) or a goat anti-
human TF polyclonal antibody (American Diagnostica, Stamford,
CT) was used.
Transfection of MV3 and WM9 cells with siRNA
The assay was performed according to the recommended
HiPerFect Transfection Reagent Traditional Protocol (Qiagen,
Hilden, Germany). Briefly, for each experiment MV3 and WM9
melanoma cells (1.5 105) were seeded in parallel on two six-well
plates (the first one for measurement of thrombin generation
and the second for control of knockdown efficiency by reverse
transcription-PCR) one day before the transfection procedure. After
24 hours of incubation at 37 1C, the cells were transfected with a
TF-specific or TM-specific siRNA, MMP-1-siRNA, Allstars-siRNA, or
a negative control siRNA (Qiagen, Cambridge, MA) at a final
concentration of 5 nM in a mix with 12 ml of HiPerFect Transfection
Reagent (Qiagen, Hilden, Germany) and 100 ml of serum-free
medium. After 2 days of incubation at 37 1C both plates were used
for further experiments.
Statistical analysis
The data are expressed as mean±SD. Statistical significance was
tested using unpaired Student’s t-test. Po0.05 indicates a significant
difference from control values.
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